Printer Friendly
The Free Library
4,719,306 articles and books
Member login
User name  
Password 
 
Join us Forgot password?

Aastrom received FDA approval to initiate multi-center trial for bone graft product.


Aastrom Biosciences, Inc., Ann Arbor, MI, announced that the FDA FDA
abbr.
Food and Drug Administration


FDA,
n.pr See Food and Drug Administration.

FDA,
n.pr the abbreviation for the Food and Drug Administration.
 has approved its Investigational New Drug (IND) application for a multi-center Phase I/II clinical trial for the company's bone generation Tissue Repair Cell (TRC TRC
Noun

(in South Africa) Truth and Reconciliation Commission: a commission which encourages people who committed human rights abuses or acts of terror during the apartheid era to reveal the truth about their crimes in return for immunity from prosecution
) stem cell product. The study will allow Aastrom's TRCs to be used at up to 3 centers for the treatment of tibial tibial

pertaining to the tibia.


tibial crest
a longitudinal prominence on the cranial border of the proximal tibia. Its proximal end (tibial tubercle) has a growth plate separate from the proximal tibia; hyperflexion injuries to
 non-union fractures. The company says if the trial is successful it could lead to a viable alternative to the current, highly morbid standard of treatment for use in the multi-million dollar bone graft market.

Aastrom says the bone graft trial protocol will combine its TRCs with a standard orthopedic matrix, to be provided by the Musculoskeletal musculoskeletal /mus·cu·lo·skel·e·tal/ (-skel´e-t'l) pertaining to or comprising the skeleton and muscles.

mus·cu·lo·skel·e·tal
adj.
Relating to or involving the muscles and the skeleton.
 Transplant Foundation (MTF (1) (Modulation Transfer Function) A measurement of monitor sharpness. MTF compares the contrast ratio between alternating black and green lines that are one pixel thick. ), Edison, NJ. The company anticipates the trial will be conducted concurrently with other planned trials in Europe that are intended to demonstrate the safety and efficacy of TRSs for bone graft indications.

Contact: Becky Anderson - (734) 930-5777, Web site: www.aastrom.com.
COPYRIGHT 2003 Transplant Communications, Inc.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2003 Gale, Cengage Learning. All rights reserved.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:Aastrom Biosciences Inc.
Publication:Transplant News
Article Type:Brief Article
Geographic Code:1USA
Date:Sep 15, 2003
Words:158
Previous Article:Amgen submits NDA to FDA for agent to treat disease associated with CHD.(new drug application)(chronic kidney disease)(Cinacalcet HCI)(Brief Article)
Next Article:AVI BioPharma begins clinical trial of West Nile virus patients.(Brief Article)
Topics:



Related Articles
Aastrom Biosciences, Loyola University perform first ever transplants of ex vivo produced stem cells in cancer patients.(Brief Article)
Aastrom Biosciences signs agreement with Mathys Medical for German bone graft clinical trial.(Bergmannsheil University Clinic is also involved)(Brief...
MTF, Aastrom form partnership to develop novel treatments for tissue regeneration.(Musculoskeletal Transplant Foundation, Aastrom Biosciences...
Aastrom Biosciences receives culture device European patent.
Aastrom Biosciences receives NIH grant to expand development of cell-base approaches for bone regeneration.(Brief Article)
ALEXION REACHES AGREEMENT WITH FDA FOR PHASE III ECULIZUMAB.
Aastrom receives patent expanding coverage for its single-pass perfusion technology.
Osiris Therapeutics receives $50 million to fund 3 ongoing adult stem cell trials.(Brief Article)
Aastrom Biosciences announces first trial of Tissue Repair Cells for regeneration of vascular tissue cells in diabetics.(clinical trials)(Brief...
AASTROM BIOSCIENCES REPORTS POSITIVE HUMAN JAW BONE RESULTS.

Terms of use | Copyright © 2009 Farlex, Inc. | Feedback | For webmasters | Submit articles